UNSPSC 51123002: Prajmaline

This classification denotes an anti-arrhythmia agent with the molecular formula C23H33N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75934UD4GJ, chemically known as ajmalanium, 17,21-dihydroxy-4-propyl-, (17r,21-alpha)- but more generally known as prajmaline, which bears US NIH Compound Identifier 37042. World Health Organization schedules prajmaline in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O.

SMILES: CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O.

UNSPSC 51123002 Prajmaline is a Commodity code that covers emergency and acute-care medications supplied to state and local health agencies, fire rescue services, and pharmacy benefit programs. State and local governments under this code procure specific pharmaceutical products—typically in bulk unit quantities with firm expiration-date requirements and short delivery windows—for use by emergency medical services, hospital systems, and multi-jurisdictional pharmacy networks. Issuing bodies span municipal fire departments, state health and human services commissions, and multi-state cooperative purchasing alliances; these entities source medications through both direct manufacturer contracts and authorized pharmaceutical wholesalers, with procurement vehicles ranging from sealed competitive bids to exploratory requests for information that precede formal solicitations.

Recent activity appears concentrated in Texas and Florida, with multi-state purchasing coordination through Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) to supply Tampa Fire Rescue, with an estimated contract value of $40,000 and a response deadline of April 8, 2026; the solicitation required nine-month minimum expiration dates, ten-day delivery, and included a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer pharmacy benefit contracting, reflecting preliminary market research ahead of formal procurement. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local facilities including Oregon, with proposals due March 26, 2026, requiring compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and featuring a two-year contract term with optional extensions through June 30, 2028.